HAdV-57 has been present in Japan since at least 2005 but was previously misidentified as HAdV-6 due to serological cross-reactivity in routine neutralization tests.
This is the authors' abstract. We don't add key points for this paper.
Neutralization tests have been routinely used for the identification of human adenovirus C species (HAdV-C) in Japan until 2007. The aim of this study was to clarify the serological cross-reactivity of antiserum that has been used exclusively in Japan and to describe the first identification of HAdV type 57 (HAdV-57) in Japan. Anti-HAdV serum to HAdV-1, 2, 5, and 6 was quantitatively evaluated for cross-reactivity to the HAdV-57 isolates. Anti-HAdV-6 serum neutralized HAdV-57 with a concentration that was 32 to 64-fold higher than what was necessary to neutralize homologous HAdV-6. HAdV-1, 2, and 5 strains were not neutralized by anti HAdV-6 serum. Furthermore, 28 HAdV-6 strains isolated from 6,476 clinical samples were re-examined for HAdVs detected in the Shimane Prefecture of Japan from 2005 to 2014. These 28 strains were re-examined by PCR-sequencing techniques using the penton, hexon, and fiber regions. 3 isolates were determined to be HAdV-57. These data show that HAdV-57 had already invaded Japan as early as 2005, and that HAdV-57 strains were misidentified as HAdV-6.
Answers are grounded in this paper and cite their sources.
Serological cross-reactivity may misclassify HAdV-57 as HAdV-6; leaves open accurate molecular surveillance in adenovirus epidemiology.
No takes yet. Share an insight, caveat, or question.
Tatsumi et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: